Shentracon Chem. (530757)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROE of 40.61% is mathematically strong, though it is contradicted by negative ROCE.
• With a market cap of only ₹26 Cr, a genuine operational revival could produce large percentage gains.
• Latest quarter's net loss rounds to ₹-0 Cr, suggesting no major immediate cash drain at this precision.

Concerns

• P/E of 331 is extreme for a company with latest quarter sales of ₹0 Cr and near-zero net profit.
• ROCE of -8.49% indicates the core business is not earning an adequate return on capital employed.
• Profit growth of -125% and Piotroski F-Score of 2/9 point to deteriorating financial health.
• Missing book value, debt/equity, and promoter holding data prevent any Graham-style margin-of-safety analysis.

AI Analysis

Let me start with what I know. At ₹59.66, Shentracon Chem has a market cap of only ₹26 Cr. That sounds small enough to be an asset play, but the price-to-earnings multiple of 331 tells me the market is paying a huge price for earnings that are barely there. The latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr, and profit growth is down 125%. A Piotroski F-Score of 2/9 is a strong warning; Graham would say the financial scorecard is poor. The reported ROE of 40.61% looks eye-catching, but the ROCE is -8.49%. That gap tells me the so-called return on equity is not coming from profitable operations; it may be an artefact of a thin book value. In commodity chemicals, there is no pricing power and no durable moat unless the company has some cost or raw-material advantage, and I see no evidence of that. Sales growth is 0.00%, no dividend is paid, and I do not have book value, debt/equity, or promoter holding data. Without book value, I cannot estimate a margin of safety. Without debt figures, I cannot judge solvency. Without promoter numbers, I cannot see owner alignment. This is not a business I can value. A possible case for this as a turnaround exists only if sales resume and ROCE turns positive. But turnaround investing requires evidence of a plan, not just a depressed share price. I need to see several quarters of real revenue, positive cash generation, and better capital efficiency before I would even open a file. Until then, Shentracon remains a speculation. I can wait.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer